Cardio Diagnostics Holdings Inc. (CDIO) is an innovative healthcare company that specializes in harnessing the power of advanced genomics and digital health to enable predictive healthcare management. This pioneering company has gained renown for its capacity to detect and predict cardiovascular disorders by setting new standards in clinical diagnostics.
Cardio Diagnostics' services are a game-changer in the health industry, prioritizing prevention over treatment. At the core of its diagnostic capabilities is the development of proprietary molecular tests and information digital platform to identify germline and somatic mutations that have propensity to cause cardiovascular disease. The overarching aim is not only to detect diseases but also to predict, prevent and customize treatment programs for each patient, bringing personalized medicine into the forefront of modern healthcare.
The company's state-of-the-art genomic testing process involves collecting biological samples from individuals, detecting specific genetic variations, and mapping these variations back to known cardiovascular genetic disease markers. The results from the tests are presented in a clear, easy-to-understand manner, ensuring that healthcare providers can accurately tailor preventative strategies for their patients.
Cardio Diagnostics also offers a unique profiling approach, which differentiates it from many other companies in its field. This consists in combining its advanced genomics screening with lifestyle behavioural and physiological variables by leveraging AI/Digital Health technologies. This enables a comprehensive, 360-degree risk assessment of a patient's cardiovascular health, allowing for far more well-informed preventative measures and treatment strategies.
As a player in the global genomics and precision medicine market, CDIO is contributing to the notable shift towards a more proactive approach in the healthcare industry, challenging the traditional one-size-fits-all model. With substantial investment in research and development, the company is constantly exploring new methodologies and technologies in pursuit of enhancing clinical outcomes, furthering overall patient engagement, and reducing healthcare costs.
In conclusion, Cardio Diagnostics Holdings is a revolutionary healthcare company evolving the landscape of cardiovascular healthcare in the use of genomics and digital health. By utilizing molecular genetics as a predictive toolset, CDIO is ushering in a new era of proactive and personalized patient care.
Income statement
Balance sheet statement
Cash flow statement
Current assets / Current liabilities
Equity / Debt / Cash
Dividends
Cardio Diagnostics Holdings, Inc. submitted its Q3 2026 Form 10-Q report, detailing condensed consolidated financial statements. Key highlights include a decrease in cash and total current assets, a drop in accounts receivable, and adjustments for a 1-for-30 reverse stock split completed in May 2025. The company is classified as a non-accelerated filer, smaller reporting company, and emerging growth company.
Cardio Diagnostics has received a federal CLIA license for its new high-complexity lab in Iowa City, Iowa, following an inspection with no deficiencies. This enables the company to process tests in-house, replacing third-party services. Management anticipates this move will improve gross margins by approximately 40% at scale due to a more controllable cost structure as test volumes increase.